Essure was marketed as a nonsurgical alternative to traditional tubal ligation and promoted as a quick, minimally invasive procedure that could be performed in a doctor’s office without general anesthesia. However, in recent years, Essure has faced scrutiny because of reports of adverse events, including persistent pain, allergic reactions, device migration, perforation of organs, and unintended pregnancies. In 2018, Bayer, the manufacturer of Essure, announced that it would discontinue the sale and distribution of Essure in the United States.